Results 41 to 50 of about 405,931 (255)

Lipoprotein-associated phospholipase A2 in relation to lipid markers: A pan-India correlation study

open access: yesAsian Journal of Medical Sciences, 2019
Background: Conventional serum markers are routinely recommended to assess heart health. However, many new biochemical markers like lipoprotein-associated phospholipase A2 (Lp-PLA2) has been studied as an efficient cardiac risk marker.
Sandhya Iyer   +4 more
doaj   +1 more source

MC-sample2-LDL-AM

open access: yes, 2017
Admixture Mapping results for LDL-cholesterol: Mexico City sample
Esteban J Parra (7852496)   +1 more
core   +1 more source

Comprehensive Characterization of 98 Chinese Cases of Genetic Creutzfeldt‐Jakob Disease With T188K Mutation

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To characterize the demographic, clinical, and laboratory features of the Chinese patients of genetic Creutzfeldt‐Jakob disease with T188K variant (T188K‐gCJD), the most common subtype of genetic prion diseases (gPrDs) in China. Methods In this nationwide retrospective study, data from 98 genetically confirmed T188K‐gCJD patients ...
Chun‐Jie Li   +11 more
wiley   +1 more source

LDL-C goal achievement rates based on the 2015 Korean guidelines and LDL-C distributions categorized by the use of lipid-modifying treatment.

open access: yes, 2020
LDL-C, low-density lipoprotein cholesterol; LMT, lipid-modifying treatment.
Siin Kim (3949709)   +5 more
core   +1 more source

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand   +5 more
wiley   +1 more source

MC-sample1-LDL-AM

open access: yes, 2017
Admixture Mapping results for LDL-cholesterol: Mexico City sample
Esteban J Parra (7852496)   +1 more
core   +1 more source

Predictive Value of Composite Inflammatory Markers for Stroke Prognosis: A Prospective Cohort Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Novel composite inflammatory markers' role in stroke prognosis is understudied, and the best predictor is unclear, requiring further exploration. Objectives This study aimed to systematically evaluate the associations of 6 novel composite inflammatory markers on stroke prognosis.
Bing Wu   +7 more
wiley   +1 more source

Diffuse MRI Edema Predicts Relapse in Cerebral Amyloid Angiopathy–Related Inflammation

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To identify MRI predictors of relapse and quantify relapse and mortality risk in cerebral amyloid angiopathy–related inflammation (CAA‐RI). A secondary objective was to assess the association between mycophenolate mofetil use and relapse risk. Methods We performed a retrospective cohort study of 36 patients with CAA‐RI treated at the
G. Abbas Kharal   +10 more
wiley   +1 more source

Ox-LDL-mediated repletion of ATP6V0d2-KD cholesterol levels restores PV volumes and impacts parasite multiplication.

open access: yes, 2019
A. Intracellular cholesterol levels displayed by nonsilenced or ATP6V0d2-KD macrophages treated or not with 50 μg/ml of ox-LDL for 48 hours, showing that ox-LDL replenishes the ~40% lower cholesterol amount of ATP6V0d2-KD to levels comparable to ...
Luiza Campos Reis (6843587)   +11 more
core   +1 more source

LDL-C response by 6-month treatment of statin or statin + ezetimibe.

open access: yes, 2023
LDL-C response by 6-month treatment of statin or statin + ezetimibe.
Joo-Hee Zo (721373)   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy